TAK-677 (Dainippon/Takeda).

Abstract

TAK-677 is a beta3-adrenergic agonist under development by Dainippon and Takeda for the potential treatment of non-insulin dependent diabetes and obesity. In March 2001, Takeda initiated a phase II trial in the US for Type II diabetes [411811], [416686], [423455]. By December 2001, the compound was also in phase II trials for obesity in the US, and Dainippon was conducting phase II studies in Japan for diabetes [458750].

• Authors: Stephan Francke
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 11 Pg. 1624-8 (Nov 2002) ISSN: 1472-4472 [Print] England
• PMID: 12476963 (Publication Type: Journal Article, Review)

Chemical References

• ((3-((2R)-(((2R)-3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yloxy)acetic acid
• Acetates
• Adrenergic beta-Agonists
• Indoles

Topics

• Acetates
• Adrenergic beta-Agonists (pharmacology, therapeutic use)
• Animals
• Diabetes Mellitus (drug therapy, metabolism)
• Diabetes Mellitus, Type 2 (drug therapy, metabolism)
• Humans
• Indoles (chemistry, pharmacology, therapeutic use)
• Obesity
• Technology, Pharmaceutical (legislation & jurisprudence, methods)